Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees

Journal of Virology

Volumn 72, Issue 2, 1998, Pages 1052-1059

  Zolla Pazner, Susan ^a,b   Lubeck, Michael ^c,i   Xu, Serena ^b   Burda, Sherri ^b   Natuk, Robert J ^d   Sinangil, Faruk ^e   Steimer, Kathelyn ^e   Gallo, Robert C ^f,j   Eichberg, Jorg W ^g   Matthews, Thomas ^h   Robert Guroff, Marjorie ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d PFIZER INC   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NATIONAL CANCER INSTITUTE   (United States)

^g Dutch Primate Center   (Netherlands)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Wyeth Lederle Vaccines and Pediat   (United States)

^j INSTITUTE OF HUMAN VIROLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CHIMPANZEE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION;

EID: 0031883256     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.2.1052-1059.1998     Document Type: Article

References (45)

1. Artenstein, A. W., J. Coppola, A. E. Brown, J. K. Carr, E. Sanders-Buell, E. Galbarini, J. R. Mascola, T. C. VanCott, P. Schonbrood, and F. E. McCutchan. 1995. Multiple introductions of HIV-1 subtype E into the western hemisphere. Lancet 346:1197-1198.
2. Arthur, L. O., S. W. Pyle, P. L. Nara, J. W. Bess, Jr., M. A. Gonda, J. C. Kelliher, R. V. Gilden, W. G. Robey, D. P. Bolognesi, R. C. Gallo, and P. J. Fischinger. 1987. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc. Natl. Acad. Sci. USA 84:8583-8587.
3. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hirshberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622-625.
4. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obijeski. 1996. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:52-59.
5. Bruck, C., C. Thiriart, L. Fabry, M. Francotte, P. Pala, O. van Opstal, J. Culp, M. Rosenberg, M. de Wilde, P. Heidt, and J. Heeney. 1994. HIV-1 envelope-elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine 12:1141-1148.
6. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recornbinant human monoclonal antibody. Science 266:1024-1027.
7. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, D. Lineberger, E. A. Emini, M. Ossorio, S. Koenig, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody 447-52D. J. Virol. 68: 6994-7000.
8. Conley, A. J., J. A. Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibodv before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
9. SF2. AIDS 9:1313-1322.
10. Emini, E. A., P. L. Nara, W. A. Schlief, J. A. Lewis, J. P. Davide, D. R. Lee, J. Kessler, S. Conley, S. Matshushita, S. D. Putney, R. J. Gerety, and J. W. Eichberg. 1990. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64:3674-3678.
11. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
12. Essex, M. 1995. The HIV-1 vaccine dilemma: lessons from the cat. J. NIH Res. 7:37-41.
13. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
14. Fultz, P. N., P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard. 1992. Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells. Science 256:1687-1690.
15. Girard, M., M.-P. Kieny, A. Pinter, F. Barre-Sinoussi, P. Nara, H. Kolbe, K. Kusumi, A. Chaput, T. Reinhart, E. Muchmore, J. Ronco, M. Kaczorek, E. Gomard, J.-C. Gluckman, and P. N. Fultz. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-546.
16. Girard, M., B. Meignier, F. Barre-Sinoussi, M.-P. Kieny, T. Matthews, E. Muchmore, P. L. Nara, Q. Wei, L. Rimsky, K. Weinhold, and P. N. Fultz. 1995. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69:6239-6248.
17. Haigwood, N. L., P. L. Nara, E. Brooks, G. A. van Nest, G. Ott, K. W. Higgins, N. Dunlop, C. J. Scandella, J. W. Eichberg, and K. S. Steimer. 1992. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66:172-182.
18. Haigwood, N. L., J. R. Shuster, G. K. Moore, H. Lee, P. V. Skiles, K. W. Higgins, P. J. Barr, C. George-Nascimento, and K. S. Steimer. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6:855-867.
19. Hilleman, M. R. 1992. Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. Vaccine 10:1053-1058.
20. Hioe, C., S. Burda, P. Chigurupati, S. Xu, and S. Zolla-Pazner. 1997. The resting cell neutralization assay for HIV-1 primary isolates. Methods Companion Methods Enzymol. 12:300-305.
21. Hioe, C. E., S. Xu, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. 1997. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9:1281-1290.
22. Lapham, C. K., J. Ouyang, B. Chandrasekhar, N. Y. Nguyen, D. S. Dimitrov, and H. Golding. 1996. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274:602-605.
23. Levy, J. A., and J. Shimabukuro. 1985. Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J. Infect. Dis. 152:734-738.
24. Louwagie, J., E. L. Delwart, J. I. Mullins, F. E. McCutchan, G. Eddy, and D. S. Burke. 1994. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genetic subtypes. AIDS Res. Hum. Retroviruses 10:561-567.
25. Lubeck, M. D., R. N. Natuk, M. Myagkikh, N. Kaylan, K. Aldrich, F. Sinangil, S. Alipanah, S. C. S. Murthy, P. K. Chanda, S. Nigida, P. D. Markham, S. Zolla-Pazner, K. Steimer, M. Wade, M. S. Reitz, Jr., L. O. Arthur, S. Mizutani, A. Davis, P. Hung, R. C. Gallo, J. Eichberg, and M. Robert-Guroff. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med. 3:651-658.
26. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler II, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
27. Murthy, K. K., E. K. Cobb, Z. El-Amad, H. Ortega, F. C. Hsueh, W. Satterfield, D. R. Lee, M. L. Kalish, N. L. Haigwood, R. C. Kennedy, K. S. Steimer, A. Schultz, and J. A. Levy. 1996. Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. AIDS Res. Hum. Retroviruses 12:1342-1348.
28. Myagkikh, M., S. Alipanah, P. D. Markham, J. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxvirus HIV-2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985-992.
29. Myers, G., B. Korber, B. Foley, K.-T. Jeang, J. W. Mellors, and S. Wain-Hobson (ed.). 1996. Human retroviruses and AIDS. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
30. Nyambi, P. N., J. Nkengasong, P. Lewi, K. Andries, W. Janssens, K. Fransen, L. Heyndrickx, P. Piot, and G. van der Groen. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235-6243.
31. Prince, A. M., H. Reesink, D. Pascual, B. Horowitz, I. Hewlett, K. K. Murthy, K. E. Cobb, and J. W. Eichberg. 1991. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7:971-973.
32. Reitz, M. S., H.-G. Guo, J. Oleske, J. Hoxie, M. Popovic, E. Read-Connole, P. Markham, H. Streicher, and R. C. Gallo. 1992. On the historical origins of HIV-1 (MN) and (RF). AIDS Res. Hum. Retroviruses 8:1539-1541. (Letter to the editor.)
33. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
34. Robert-Guroff, M. 1990. Neutralizing antibodies, p. 179-183. In M. M. Aldovini and B. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
35. Sawyer, L. W., M. T. Wrin, L. Crawford-Miksza, B. Potts, Y. We, P. A. Weber, R. D. Alfonso, and C. V. Hanson. 1994. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68:1342-1349.
36. Scarlatti, G., J. Albert, P. Rossi, V. Hodara, P. Biraghi, L. Muggiasca, and E. M. Fenyo. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168:207-210.
37. Shearer, G. M., and M. Clerici. 1996. Protective immunity against HIV infection: has nature done the experiment for us? Immunol. Today 17:21-24.
38. Shibata, R., C. Siemon, M. W. Cho, L. O. Arthur, S. M. Nigida, Jr., T. Matthews, L. A. Sawyer, A. Schultz, K. K. Murthy, Z. Israel, A. Javadian, P. Frost, R. C. Kennedy, H. C. Lane, and M. A. Martin. 1996. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70: 4361-4369.
39. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
40. Weber, J., E.-M. Fenyö, S. Beddows, P. Kaleebu, Å. Björndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
41. Wrin, R., T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. F. Nunberg. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48.
42. York-Higgins, D., C. Cheng-Mayer, D. Bauer, J. A. Levy, and D. Dina. 1990. Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J. Virol. 64:4016-4020.
43. Zolla-Pazner, S., C. Alving, R. Belshe, P. Berman, S. Burda, P. Chigurupati, M. L. Clements, A.-M. Duliege, J.-L. Excler, J. Kahn, M. J. McElrath, S. Sharpe, F. Sinangil, K. Steimer, M. C. Walker, N. Wassef, and S. Xu. 1997. Neutralization of a clade B primary isolate by sera from HIV-uninfected recipients of candidate AIDS vaccines. J. Infect. Dis. 175:764-774.
44. Zolla-Pazner, S., J. O'Leary, S. Burda, M. K. Gorny, M. Kim, J. Mascola, and F. McCutchan. 1995. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69:3807-3815.
45. Zolla-Pazner, S., and S. Sharpe. 1995. A resting cell assay for improved detection of antibody-mediated neutralization of HIV-1 primary isolates. AIDS Res. Hum. Retroviruses 11:1449-1457.